Kenneth Blum

Q: What Schools Are Affiliated With Kenneth Blum

Kenneth Blum is affiliated with the following schools: University of North Texas, University of Florida College of Medicine, Western University of Health Sciences, University of Vermont, Wake Forest University, University of Florida, University of Szeged, University of Southern California, Stanford University, University of Colorado

Kenneth Blum's AcademicInfluence.com Rankings

Kenneth Blum

Biology

#5644

World Rank

#8173

Historical Rank

Neuroscience

#1034

World Rank

#1076

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Kenneth Blum Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Kenneth Blum is an American scientist who has studied neuropsychopharmacology and genetics. Until 1995 he was a professor of Pharmacology at the University of Texas Health Science Center at San Antonio.

(See a Problem?)

Kenneth Blum's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Allelic association of human dopamine D2 receptor gene in alcoholism. (1990) (968)
The Reward Deficiency Syndrome: A Biogenetic Model for the Diagnosis and Treatment of Impulsive, Addictive and Compulsive Behaviors (2000) (898)
Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. (1991) (676)
Reward deficiency syndrome: genetic aspects of behavioral disorders. (2000) (646)
REWARD DEFICIENCY SYNDROME (1996) (513)
The D2 Dopamine Receptor Gene as a Determinant of Reward Deficiency Syndrome (1996) (439)
Weight Gain Is Associated with Reduced Striatal Response to Palatable Food (2010) (356)
Allelic association of the D2 dopamine receptor gene with cocaine dependence. (1993) (273)
Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. (1995) (271)
Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. (1991) (212)
"Liking" and "wanting" linked to Reward Deficiency Syndrome (RDS): hypothesizing differential responsivity in brain reward circuitry. (2012) (205)
Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary (2008) (191)
No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. (1994) (187)
Attention-deficit-hyperactivity disorder and reward deficiency syndrome (2008) (170)
Genetic Addiction Risk Score (GARS): Molecular Neurogenetic Evidence for Predisposition to Reward Deficiency Syndrome (RDS) (2014) (161)
Dopamine and glucose, obesity, and reward deficiency syndrome (2014) (160)
The Addictive Brain: All Roads Lead to Dopamine (2012) (158)
Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of "super normal controls" in psychiatricgenetic research of complex behavioral disorders. (2005) (158)
Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. (1996) (156)
Substance abuse vulnerability and D2 receptor genes (1993) (137)
Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB) (1997) (130)
rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts (2015) (129)
Overcoming qEEG Abnormalities and Reward Gene Deficits during Protracted Abstinence in Male Psychostimulant and Polydrug Abusers Utilizing Putative Dopamine D2 Agonist Therapy: Part 2 (2010) (122)
Genetic predisposition in alcoholism: association of the D2 dopamine receptor TaqI B1 RFLP with severe alcoholics. (1993) (121)
Generational Association Studies of Dopaminergic Genes in Reward Deficiency Syndrome (RDS) Subjects: Selecting Appropriate Phenotypes for Reward Dependence Behaviors (2011) (118)
The D2 dopamine receptor gene as a predictor of compulsive disease: Bayes' theorem. (1995) (105)
Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems. (2018) (100)
Handbook of Psychiatric Genetics (1996) (100)
Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence. (2018) (96)
Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction (2015) (96)
Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z (2017) (95)
Reward circuitry dopaminergic activation regulates food and drug craving behavior. (2011) (94)
Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric (2014) (93)
Dopamine D2 receptor Taq A1 allele predicts treatment compliance of LG839 in a subset analysis of pilot study in the Netherlands (2008) (90)
Epigenetics in Developmental Disorder: ADHD and Endophenotypes. (2011) (88)
Dopamine homeostasis: brain functional connectivity in reward deficiency syndrome. (2017) (88)
Sex, Drugs, and Rock ‘N’ Roll: Hypothesizing Common Mesolimbic Activation as a Function of Reward Gene Polymorphisms (2012) (86)
Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions. (2009) (84)
Systematic Evaluation of “Compliance” to Prescribed Treatment Medications and “Abstinence” from Psychoactive Drug Abuse in Chemical Dependence Programs: Data from the Comprehensive Analysis of Reported Drugs (2014) (82)
Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). (2007) (82)
Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: double-blind placebo-controlled study of the nutritional adjunct SAAVE. (1988) (81)
12. – ALCOHOL AND OPIATES: A REVIEW OF COMMON NEUROCHEMICAL AND BEHAVIORAL MECHANISMS (1977) (76)
Long Term Suboxone™ Emotional Reactivity As Measured by Automatic Detection in Speech (2013) (75)
Exoproteome and Secretome Derived Broad Spectrum Novel Drug and Vaccine Candidates in Vibrio cholerae Targeted by Piper betel Derived Compounds (2013) (74)
Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note. (2013) (73)
Neurogenetics of Dopaminergic Receptor Supersensitivity in Activation of Brain Reward Circuitry and Relapse: Proposing “Deprivation-Amplification Relapse Therapy” (DART) (2009) (73)
Nutrigenomic targeting of carbohydrate craving behavior: can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map? (2009) (70)
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner? (2015) (70)
Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape (2016) (70)
The Molecular Neurobiology of Twelve Steps Program & Fellowship: Connecting the Dots for Recovery (2015) (69)
Correlation of the Taq1 dopamine D2 receptor gene and percent body fat in obese and screened control subjects: a preliminary report. (2012) (68)
A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone (2018) (67)
Fifty Years in the Development of a Glutaminergic-Dopaminergic Optimization Complex (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome: A Pictorial. (2016) (66)
Low Dopamine Function in Attention Deficit/Hyperactivity Disorder: Should Genotyping Signify Early Diagnosis in Children? (2014) (66)
Neurodynamics of relapse prevention: a neuronutrient approach to outpatient DUI offenders. (1990) (64)
Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms. (2012) (64)
The Psychoactive Designer Drug and Bath Salt Constituent MDPV Causes Widespread Disruption of Brain Functional Connectivity (2016) (63)
Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With “Dopamine Homeostasis” in Reward Deficiency Syndrome (RDS) (2017) (63)
Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability (2010) (62)
The Benefits of Genetic Addiction Risk Score (GARS™) Testing in Substance Use Disorder (SUD). (2018) (61)
GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM™): LESSONS LEARNED FROM AMERICA. (2017) (61)
Reward deficiency syndrome in obesity: A preliminary cross-sectional trial with a genotrim variant (2006) (60)
Opioid Substitution Therapy: Achieving Harm Reduction While Searching for a Prophylactic Solution. (2019) (58)
Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term (2016) (57)
Conceptualizing Addiction From an Osteopathic Perspective: Dopamine Homeostasis (2018) (57)
Acute Intravenous Synaptamine Complex Variant KB220™ “Normalizes” Neurological Dysregulation in Patients during Protracted Abstinence from Alcohol and Opiates as Observed Using Quantitative Electroencephalographic and Genetic Analysis for Reward Polymorphisms: Part 1, Pilot Study with 2 Case Reports (2010) (57)
Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. (2004) (56)
BARHL1 Is Downregulated in Alzheimer’s Disease and May Regulate Cognitive Functions through ESR1 and Multiple Pathways (2017) (56)
Neuro-Genetics of Reward Deficiency Syndrome (RDS) as the Root Cause of "Addiction Transfer": A New Phenomenon Common after Bariatric Surgery. (2011) (56)
The genetics of problem and pathological gambling: a systematic review. (2014) (55)
Alcohol and opiates : neurochemical and behavioral mechanisms (1977) (55)
P300 (Latency) Event-Related Potential: An Accurate Predictor of Memory Impairment (2003) (55)
Genetic Addiction Risk Score (GARS™) as a Predictor of Substance Use Disorder: Identifying Predisposition Not Diagnosis. (2018) (54)
Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis. (2018) (54)
NEUROGENETIC IMPAIRMENTS OF BRAIN REWARD CIRCUITRY LINKS TO REWARD DEFICIENCY SYNDROME (RDS) AS EVIDENCED BY GENETIC ADDICTION RISK SCORE (GARS): A CASE STUDY (2013) (54)
Neurogenetics and Epigenetics in Impulsive Behaviour: Impact on Reward Circuitry. (2012) (53)
Insurance Companies Fighting the Peer Review Empire without any Validity: the Case for Addiction and Pain Modalities in the face of an American Drug Epidemic. (2018) (53)
Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis. (2007) (52)
Introducing "Precision Addiction Management (PAM®)" as an Adjunctive Genetic Guided Therapy for Abusable Drugs in America. (2018) (52)
Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and Leptin genes and up-regulation of the adiponectin gene (2008) (50)
Dopamine Genetics and Function in Food and Substance Abuse. (2013) (50)
Neurogenetic and epigenetic correlates of adolescent predisposition to and risk for addictive behaviors as a function of prefrontal cortex dysregulation. (2015) (50)
LG839: Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome (2008) (49)
Reduction of both drug hunger and withdrawal against advice rate of cocaine abusers in a 30-day inpatient treatment program by the neuronutrient tropamine (1988) (49)
Neurogenetics and Clinical Evidence for the Putative Activation of the Brain Reward Circuitry by a Neuroadaptagen: Proposing an Addiction Candidate Gene Panel Map (2011) (49)
Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD). (2017) (48)
Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors (2018) (48)
Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on Reward Deficiency Syndrome (RDS). (2010) (48)
Prolonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele. (1994) (44)
Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis. (2011) (42)
Neurogenetic interactions and aberrant behavioral co-morbidity of attention deficit hyperactivity disorder (ADHD): dispelling myths (2005) (41)
The effects of residential dual diagnosis treatment on alcohol abuse (2017) (41)
Lack of association between alcohol-dependence and D3 dopamine receptor gene in three independent samples. (1995) (41)
Epigenetic Modulation of Mood Disorders. (2013) (41)
Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration: a pilot study. (1988) (40)
Opioid peptides and alcoholism: genetic deficiency and chemical management. (1986) (39)
Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation. (2012) (37)
Putative Dopamine Agonist (KB220Z) Attenuates Lucid Nightmares in PTSD Patients: Role of Enhanced Brain Reward Functional Connectivity and Homeostasis Redeeming Joy (2015) (37)
Handbook of abusable drugs (1984) (36)
Alcohol and opioid peptides: neuropharmacological rationale for physical craving of alcohol. (1987) (36)
NIDA-Drug Addiction Treatment Outcome Study (DATOS) Relapse as a Function of Spirituality/Religiosity (2015) (36)
The Food and Drug Addiction Epidemic: Targeting Dopamine Homeostasis. (2017) (35)
Co-occurrences of substance use and other potentially addictive behaviors: Epidemiological results from the Psychological and Genetic Factors of the Addictive Behaviors (PGA) Study (2020) (35)
The dopamine D2 receptor gene and alcoholism. (1991) (35)
Alcoholism and the D2 dopamine receptor gene. (1993) (34)
Precision Behavioral Management (PBM): A Novel Genetically Guided Therapy to Combat Reward Deficiency Syndrome (RDS) Relevant to the Opiate Crisis (2020) (32)
Gene Narcotic Attenuation Program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome (2007) (32)
Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair. (2019) (32)
Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land? (2015) (32)
Enhancement of Attention Processing by Kantroll™ in Healthy Humans: A Pilot Study (1997) (31)
Steroid receptors and disease : cancer, autoimmune, bone, and circulatory disorders (1988) (31)
Neuronutrient effects on weight loss in carbohydrate bingers: an open clinical trial. (1990) (30)
A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer (2013) (29)
KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit? (2016) (29)
Using the Neuroadaptagen KB200z™ to Ameliorate Terrifying, Lucid Nightmares in RDS Patients: the Role of Enhanced, Brain-Reward, Functional Connectivity and Dopaminergic Homeostasis (2015) (29)
Neuropsychopharmacology and Neurogenetic Aspects of Executive Functioning: Should Reward Gene Polymorphisms Constitute a Diagnostic Tool to Identify Individuals at Risk for Impaired Judgment? (2012) (28)
Synaptamine (SG8839),TM An Amino-Acid Enkephalinase Inhibition Nutraceutical Improves Recovery of Alcoholics, A Subtype of Reward Deficiency Syndrome (RDS) (2007) (28)
Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence (2013) (28)
Dopamine D2 gene expression interacts with environmental enrichment to impact lifespan and behavior (2016) (27)
Putative targeting of Dopamine D2 receptor function in Reward Deficiency Syndrome (RDS) by Synaptamine Complex™ Variant (KB220): Clinical trial showing anti-anxiety effects (2009) (27)
Delayed P300 latency correlates with abnormal Test of Variables of Attention (TOVA) in adults and predicts early cognitive decline in a clinical setting (2006) (27)
THE BENEFITS OF CUSTOMIZED DNA DIRECTED NUTRITION TO BALANCE THE BRAIN REWARD CIRCUITRY AND REDUCE ADDICTIVE BEHAVIORS. (2016) (27)
A short term pilot open label study to evaluate efficacy and safety of LG839, a customized DNA directed nutraceutical in obesity: Exploring Nutrigenomics (2008) (27)
Improvement of cocaine-induced neuromodulator deficits by the neuronutrient Tropamine. (1988) (26)
Conserved host-pathogen PPIs. Globally conserved inter-species bacterial PPIs based conserved host-pathogen interactome derived novel target in C. pseudotuberculosis, C. diphtheriae, M. tuberculosis, C. ulcerans, Y. pestis, and E. coli targeted by Piper betel compounds. (2013) (26)
Advances in therapy. (1971) (26)
Apolipoprotein Gene Polymorphisms (APOB, APOC111, APOE) in the Development of Coronary Heart Disease in Ethnic Groups of Kazakhstan (2014) (26)
Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (NAAT)™ Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study (2012) (26)
Buprenorphine Response as a Function of Neurogenetic Polymorphic Antecedents: Can Dopamine Genes Affect Clinical Outcomes in Reward Deficiency Syndrome (RDS)? (2014) (26)
Hypothesizing that designer drugs containing cathinones ("bath salts") have profound neuro-inflammatory effects and dangerous neurotoxic response following human consumption. (2013) (25)
Managing Terrorism or Accidental Nuclear Errors, Preparing for Iodine-131 Emergencies: A Comprehensive Review (2014) (25)
Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS) (2020) (25)
Folate nutrigenetics: a convergence of dietary folate metabolism, folic acid supplementation, and folate antagonist pharmacogenetics. (2007) (25)
Can the Chronic Administration of the Combination of Buprenorphine and Naloxone Block Dopaminergic Activity Causing Anti-reward and Relapse Potential? (2011) (25)
The H-Wave® device is an effective and safe non-pharmacological analgesic for chronic pain: a meta-analysis (2008) (24)
Repetitive H-Wave® device stimulation and program induces significant increases in the range of motion of post operative rotator cuff reconstruction in a double-blinded randomized placebo controlled human study (2009) (23)
A Shared Molecular and Genetic Basis for Food and Drug Addiction: Overcoming Hypodopaminergic Trait/State by Incorporating Dopamine Agonistic Therapy in Psychiatry. (2015) (23)
Preliminary association of both the Dopamine D2 Receptor (DRD2) (Taq1 A1 Allele) and the Dopamine Transporter (DAT1) (480 bp Allele) genes with pathological aggressive behavior, a clinical subtype of Reward Deficiency Syndrome (RDS) in adolescents (2007) (23)
Substance use disorder a bio-directional subset of reward deficiency syndrome. (2017) (23)
Peyote, a potential ethnopharmacologic agent for alcoholism and other drug dependencies: possible biochemical rationale. (1977) (23)
GENETIC ADDICTION RISK SCORE (GARS) ANALYSIS: EXPLORATORY DEVELOPMENT OF POLYMORPHIC RISK ALLELES IN POLY-DRUG ADDICTED MALES (2010) (22)
Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome? (2020) (22)
MODIFICATION OF P300 AMPLITUDE AND OTHER ELECTROPHYSIOLOGICAL PARAMETERS OF DRUG ABUSE BY CRANIAL ELECTRICAL STIMULATION (1990) (21)
OMICS : Biomedical Perspectives and Applications (2011) (21)
Have We Hatched the Addiction Egg: Reward Deficiency Syndrome Solution System™ (2013) (21)
Diagnosis and Healing In Veterans Suspected of Suffering from Post-Traumatic Stress Disorder (PTSD) Using Reward Gene Testing and Reward Circuitry Natural Dopaminergic Activation. (2012) (21)
Alcohol euphoria: possible mediation via endorphinergic mechanisms. (1979) (21)
Neuropsychiatric Genetics of Happiness, Friendships, and Politics: Hypothesizing Homophily ("Birds of a Feather Flock Together") as a Function of Reward Gene Polymorphisms. (2012) (20)
Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization (2019) (20)
Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior. (2014) (19)
The H-Wave® Device Induces NO-dependent Augmented Microcirculation and Angiogenesis, Providing Both Analgesia and Tissue Healing in Sports Injuries (2008) (19)
Neurogenetic deficits caused by alcoholism: restoration by SAAVE, a neuronutrient intervention adjunct. (1988) (19)
Low-Resolution Electromagnetic Tomography (LORETA) of changed Brain Function Provoked by Pro-Dopamine Regulator (KB220z) in one Adult ADHD case. (2016) (19)
Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD) (2019) (19)
Hypothesizing repetitive paraphilia behavior of a medication refractive Tourette's syndrome patient having rapid clinical attenuation with KB220Z-nutrigenomic amino-acid therapy (NAAT). (2013) (18)
Alcoholism: scientific basis of a neuropsychogenetic disease. (1988) (18)
Pharmacotherapies for Overeating and Obesity. (2013) (18)
The DRD2 Taq1A A1 Allele May Magnify the Risk of Alzheimer’s in Aging African-Americans (2018) (18)
DNA based customized nutraceutical "gene therapy" utilizing a genoscore: a hypothesized paradigm shift of a novel approach to the diagnosis, stratification, prognosis and treatment of inflammatory processes in the human. (2006) (18)
Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine (2019) (18)
A novel multi-omics-based highly accurate prediction of symptoms, comorbid conditions, and possible long-term complications of COVID-19. (2021) (17)
Administration of a putative pro-dopamine regulator, a neuronutrient, mitigates alcohol intake in alcohol-preferring rats (2020) (17)
Addiction Treatment in America: After Money or Aftercare? (2015) (17)
Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms (2015) (17)
Hypothesizing Music Intervention Enhances Brain Functional Connectivity Involving Dopaminergic Recruitment: Common Neuro-correlates to Abusable Drugs (2017) (17)
Age-related increases in parathyroid hormone may be antecedent to both osteoporosis and dementia (2009) (16)
Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment? (2016) (16)
Reward Deficiency Syndrome: Attentional/Arousal Subtypes, Limitations of Current Diagnostic Nosology, and Future Research (2015) (16)
In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing. (2020) (16)
The H-Wave® small muscle fiber stimulator, a nonpharmacologic alternative for the treatment of chronic soft-tissue injury and neuropathic pain: an extended population observational study (2006) (16)
The effect of dopamine and other catecholamines on neuromuscular transmission. (1969) (16)
Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics (2015) (16)
Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia (2010) (16)
Pro-Dopamine Regulator – (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS) (2017) (16)
Neurophysiological Measures and Alcohol Use Disorder (AUD): Hypothesizing Links between Clinical Severity Index and Molecular Neurobiological Patterns (2014) (15)
Putative COVID- 19 Induction of Reward Deficiency Syndrome (RDS) and Associated Behavioral Addictions with Potential Concomitant Dopamine Depletion: Is COVID-19 Social Distancing a Double Edged Sword? (2020) (15)
Death by Opioids: Are there non-addictive scientific solutions? (2019) (15)
“Cold” X5 Hairlaser™ used to treat male androgenic alopecia and hair growth: an uncontrolled pilot study (2014) (15)
Chromium Picolinate (CrP) a putative anti-obesity nutrient induces changes in body composition as a function of the Taq1 dopamine D2 receptor polymorphisms in a randomized double-blind placebo controlled study (2007) (15)
Hypothesizing that Marijuana Smokers are at a Significantly Lower Risk of Carcinogenicity Relative to Tobacco-Non-Marijuana Smokers: Evidenced Based on Statistical Reevaluation of Current Literature (2008) (15)
Substance Use Disorder Exacerbates Brain Electrophysiological Abnormalities in a Psychiatrically-III Population (1996) (15)
Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction (2015) (15)
High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial (2021) (15)
Psychostimulant use disorder emphasizing methamphetamine and the opioid -dopamine connection: Digging out of a hypodopaminergic ditch (2020) (15)
H-wave®, a nonpharmacologic alternative for the treatment of patients with chronic soft tissue inflammation and neuropathic pain: A preliminary statistical outcome study (2006) (14)
Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD (2018) (14)
“Dopamine homeostasis” requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America’s drug epidemic (2017) (14)
Reviewing the role of putative candidate genes in "Neurobesigenics," a clinical subtype of Reward Deficiency Syndrome (RDS) (2007) (14)
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse. (2018) (14)
The therapeutic potential of exercise for neuropsychiatric diseases: A review (2020) (14)
Hoehn and Yahr staging of Parkinson's disease in relation to neuropsychological measures. (2018) (14)
A Novel Precision Approach to Overcome the “Addiction Pandemic” by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration (2021) (13)
miRegulome: a knowledge-base of miRNA regulomics and analysis (2015) (13)
Hypothesizing Synergy between Acupuncture/ Auriculotherapy and Natural Activation of Mesolimbic Dopaminergic Pathways: Putative Natural Treatment Modalities for the Reduction of Drug Hunger and Relapse (2011) (13)
Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)? (2018) (13)
Attention-de fi cit-hyperactivity disorder and reward de fi ciency syndrome (2008) (13)
Drug Abuse Relapse Rates Linked to Level of Education: Can We Repair Hypodopaminergic-Induced Cognitive Decline With Nutrient Therapy? (2014) (13)
H‐Wave® induces arteriolar vasodilation in rat striated muscle via nitric oxide‐mediated mechanisms (2009) (12)
Our evolved unique pleasure circuit makes humans different from apes: Reconsideration of data derived from animal studies (2018) (12)
Innate properties of H-Wave device, a small fiber stimulator provides the basis for a paradigm shift of electro-therapeutic treatment of pain with increased functional restoration associated with human neuropathies by affecting tissue circulation: a hypothesis. (2005) (12)
Pre-clinical models of reward deficiency syndrome: A behavioral octopus (2020) (12)
Preliminary investigation of plasma levels of sex hormones and human growth factor(s), and P300 latency as correlates to cognitive decline as a function of gender (2009) (12)
Alcohol and the addictive brain : new hope for alcoholics from biogenetic research (1991) (12)
Alcohol and central nervous system peptides. (1983) (12)
Declinol, a Complex Containing Kudzu, Bitter Herbs (Gentian, Tangerine Peel) and Bupleurum, Significantly Reduced Alcohol Use Disorders Identification Test (AUDIT) Scores in Moderate to Heavy Drinkers: A Pilot Study. (2013) (11)
Overload: Attention Deficit Disorder and the Addictive Brain (1996) (11)
Genetic Addiction Risk Score (GARS): Testing For Polygenetic Predisposition and Risk to Reward Deficiency Syndrome (RDS) (2011) (11)
Pilot clinical observations between food and drug seeking derived from fifty cases attending an eating disorder clinic (2016) (11)
Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity. (2016) (11)
Evoked Potentials and Neuropsychological Tests Validate Positron Emission Topography (PET) Brain Metabolism in Cognitively Impaired Patients (2013) (11)
Neurogenetics of acute and chronic opiate/opioid abstinence: treating symptoms and the cause. (2017) (10)
Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality (2015) (10)
Development and validation of the Reward Deficiency Syndrome Questionnaire (RDSQ-29) (2022) (10)
Alcohol and alcoholism. (1981) (10)
Lyme and Dopaminergic Function: Hypothesizing Reduced Reward Deficiency Symptomatology by Regulating Dopamine Transmission (2017) (10)
ISOQUINOLINE ALKALOIDS AS POSSIBLE REGULATORS OF ALCOHOL ADDICTION (1977) (10)
Depressive States Induced by Drugs of Abuse: Clinical Evidence, Theoretical Mechanisms and Proposed Treatment Part II (1976) (9)
Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions (2021) (9)
Molecular Neurobiology of Addiction Recovery (2013) (9)
Hypothesizing that a Pro-Dopaminergic Regulator (KB220z™ Liquid Variant) can Induce “Dopamine Homeostasis” and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence (2016) (9)
Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual (2020) (9)
Folk medicine and herbal healing (1981) (9)
“Pro-dopamine regulation (KB220Z™)” as a long-term therapeutic modality to overcome reduced resting state dopamine tone in opiate/opioid epidemic in America (2016) (9)
Genospirituality: Our Beliefs, Our Genomes, and Addictions (2013) (9)
Neurogenetics and Nutrigenomics of Reward Deficiency Syndrome (2011) (9)
Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: Evidence supported by structural equation modeling (SEM) parameter estimates (2007) (9)
H-Wave® effects on blood flow and angiogenesis in longitudinal studies in rats. (2011) (9)
Can Genetic Testing Coupled with Enhanced Dopaminergic Activation Reduce Recidivism Rates in the Workers Compensation Legacy Cases? (2014) (8)
Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) During Adolescent Brain Development. (2021) (8)
Physical Exercise Interventions for Drug Addictive Disorders (2017) (8)
Nutrition Programs Enhance Exercise Effects on Body Composition and Resting Blood Pressure (2013) (8)
Hypothesizing Darkness Induced Alcohol Intake Linked to Dopaminergic Regulation of Brain Function. (2014) (8)
Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake (2016) (8)
Evoked Potentials and Memory/Cognition Tests Validate Brain Atrophy as Measured by 3T MRI (NeuroQuant) in Cognitively Impaired Patients (2015) (8)
Observations on the Coronary Vasodilator Effect of ‘Persantin’ (1961) (8)
Pharmacological Inhibition of Brain Fatty Acid Binding Protein Reduces Ethanol Consumption in Mice (2017) (8)
Audio Therapy Significantly Attenuates Aberrant Mood in Residential Patient Addiction Treatment: Putative Activation of Dopaminergic Pathways in the Meso-Limbic Reward Circuitry of Humans (2013) (8)
Acupuncture as a Common Mode of Treatment for Drug Dependence: Possible Neurochemical Mechanisms (1978) (8)
Menopause Analytical Hormonal Correlate Outcome Study (MAHCOS) and the Association to Brain Electrophysiology (P300) in a Clinical Setting (2014) (8)
Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It “Blowin’ in the Wind”? (2022) (8)
The benefits of genetic addiction risk score (GARS™) and pro-dopamine regulation in combating suicide in the American Indian population. (2018) (7)
Improvement of long-term memory access with a pro-dopamine regulator in an elderly male: Are we targeting dopamine tone? (2017) (7)
Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis (2021) (7)
Can Genetic Testing Provide Information to Develop Customized Nutrigenomic Solutions for Reward Deficiency Syndrome? (2015) (7)
Nutrigenomics and pharmacogenomics: a scientific wonderland (2006) (7)
Common Phenotype in Patients with Both Food and Substance Dependence: Case Reports. (2013) (7)
A COMMENTARY ON BRAIN MAPPING IN 60 SUBSTANCE ABUSERS : CAN THE POTENTIAL FOR DRUG ABUSE BE PREDICTED AND PREVENTED BY TREATMENT ? (1990) (6)
Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency (2020) (6)
109-5 Association of polymorphisms of dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB) and pathological violence (PV) (1997) (6)
Dopaminergic Neurogenetics of Sleep Disorders in Reward Deficiency Syndrome (RDS). (2014) (6)
Enhancing Brain Pregnenolone May Protect Cannabis Intoxication but Should Not Be Considered as an Anti-addiction Therapeutic: Hypothesizing Dopaminergic Blockade and Promoting Anti-Reward (2015) (6)
To Binge or Not To Binge (1999) (6)
Americas’ opioid/psychostimulant epidemic would benefit from general population early identification of genetic addiction risk especially in children of alcoholics (COAs) (2019) (6)
Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility (2015) (6)
Healing enhancement of chronic venous stasis ulcers utilizing H-WAVE® device therapy: a case series (2010) (6)
Correction: Long Term Suboxone™ Emotional Reactivity As Measured by Automatic Detection in Speech (2013) (6)
Review: Cannabinoids as Medicinals (2022) (6)
Global Evidence for the Key Role of the Dopamine D2 Receptor Gene (DRD2) and DRD2 Receptors in Alcoholism (2017) (6)
Molecular neuro-biological and systemic health benefits of achieving dopamine homeostasis in the face of a catastrophic pandemic (COVID- 19): A mechanistic exploration. (2020) (6)
Research Advances in Alcohol and Drug Problems, Vol. 7 (1984) (5)
Retraction: Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics (2015) (5)
Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics (2015) (5)
UNDERSTANDING THE HIGH MIND: HUMANS ARE STILL EVOLVING GENETICALLY (2011) (5)
Neurobiology and Spirituality in Addiction Recovery. (2021) (5)
Chronic treatment and abstinence from methylphenidate exposure dose-dependently changes glucose metabolism in the rat brain (2022) (5)
Neurogenetics and Neurobiology of Dopamine in Anhedonia (2014) (5)
A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing “Precision Behavioral Management” (2021) (5)
Health economics of nutrigenomics in weight management (2008) (5)
Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors (2022) (5)
P300 (latency) event-related potential: An accurate predictor of memory impairment : Hormonal correlates (2005) (5)
Critical Analysis of White House Anti-Drug Plan (2017) (4)
Genetic Addiction Risk Scores (GARS) coupled with the Comprehensive Analysis of Reported Drugs (CARD) provide diagnostic and outcome data supporting the need for dopamine D2 agonist therapy: Proposing a holistic -therapeutic model for Reward Deficiency Syndrome (RDS) (2013) (4)
Proposing a “Brain Health Checkup (BHC)” as a Global Potential “Standard of Care” to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of “Dopamine Homeostasis” (2022) (4)
Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction? (2021) (4)
Dopamine D2 receptor gene polymorphisms in Scandinavian chronic alcoholics: A reappraisal (2005) (4)
Epigenetic Repair of Terrifying Lucid Dreams by Enhanced Brain Reward Functional Connectivity and Induction of Dopaminergic Homeostatic Signaling. (2021) (4)
Everything you Need to Know about Global Alcohol Policy (2013) (4)
The Marc Pro TM Device Improves Muscle Performance and Recovery from Concentric and Eccentric Exercise Induced Muscle Fatigue in Humans: A Pilot Study (2011) (4)
A Proposed Brain-, Spine-, and Mental- Health Screening Methodology (NEUROSCREEN) for Healthcare Systems: Position of the Society for Brain Mapping and Therapeutics. (2022) (4)
Should We Embrace Vaccines for Treating Substance- Related Disorder, A Subset of Reward Deficiency Syndrome (RDS)? (2015) (4)
FOXN3 and GDNF Polymorphisms as Common Genetic Factors of Substance Use and Addictive Behaviors (2022) (4)
Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality? (2021) (4)
ALLELIC ASSOCIATION OF THE D2 DOPAMINE RECEPTOR GENE IN COCAINEDEPENDENCE. (1992) (4)
Do We Really Need to Continue Pharmacotherapy for Opioid Use Disorder (OUD) Indefinitely (2015) (4)
Acute and chronic interactions between ethanol and peptide opiates (1980) (3)
Clinical Practices that can Combat Endemic Legal Opioid Dependence: Genetic Addiction Risk Score (GARS)Ã¢ÂÂ¢, KB220ZÃ¢ÂÂ¢, Comprehensive Analysis of Reported Drugs (CARD) and Electrotherapy (2013) (3)
Brain Mapping the Effects of Chronic Aerobic Exercise in the Rat Brain Using FDG PET (2022) (3)
Hypothesizing High Negative Emotionality as a Function of Genetic Addiction Risk Severity (GARS) Testing in Alcohol Use Disorder (AUD) (2020) (3)
Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case–Control Subjects (2022) (3)
Overcoming reward deficiency syndrome by the induction of “dopamine homeostasis” instead of opioids for addiction: illusion or reality? (2022) (3)
Low and Normal IGF-1 Levels in Patients with Chronic Medical Disorders (CMD) is Independent of Anterior Pituitary Hormone Deficiencies: Implications for Treating IGF-1 Abnormal Deficiencies with CMD. (2013) (3)
Neurogenetic and Epigenetic Aspects of Cannabinoids (2022) (3)
Psychoactive Drugs Like Cannabis -Induce Hypodopaminergic Anhedonia and Neuropsychological Dysfunction in Humans: Putative Induction of Dopamine Homeostasis via Coupling of Genetic Addiction Risk Severity (GARS) testing and Precision Pro-dopamine Regulation (KB220). (2021) (3)
Adult growth hormone deficiency treatment with a combination of growth hormone and insulin-like growth factor-1 resulting in elevated sustainable insulin-like growth factor-1 and insulin-like growth factor binding protein 3 plasma levels: a case report (2010) (3)
Induction of homeostatic biological parameters in reward deficiency as a function of an iron-free multi-nutrient complex: Promoting hemoglobinization, aerobic metabolism, viral immuno-competence, and neuroinflammatory regulation (2020) (3)
Hypothesizing Las Vegas and Sutherland Springs Mass Shooters Suffer from Reward Deficiency Syndrome: “Born Bad” (2017) (3)
[The coronary vasodilator effect of Persantin]. (1961) (3)
Attention-defi cit-hyperactivity disorder and reward defi ciency syndrome (2008) (3)
Effects of Electrical Stimulation Using the Marc protm Device during the Recovery Period on Calf Muscle Strength and Fatigue in Adult Fitness Participants (2013) (3)
Addiction Research and Therapy in the 21st Century: Providing a Forum for Evidence -Based Addiction Medicine (2013) (3)
Quantitative Electroencephalography Analysis (qEEG) of Neuro-Electro-Adaptive Therapy 12™ [NEAT12] Up-Regulates Cortical Potentials in an Alcoholic during Protracted Abstinence: Putative Anti-Craving Implications (2015) (3)
Frequency of the Dopamine Receptor D3 (rs6280) vs. Opioid Receptor µ1 (rs1799971) Polymorphic Risk Alleles in Patients with Opioid Use Disorder: A Preponderance of Dopaminergic Mechanisms? (2022) (3)
Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry? (2022) (3)
A Multi-Locus Approach to Treating Fibromyalgia by Boosting Dopaminergic Activity in the Meso-Limbic System of the Brain (2014) (3)
DRD2 A1 allele and P300 abnormalities in obesity (1994) (3)
The effect of VMP35 supplement ingredients encapsulated in a novel Phospholipid Prodosome SK713 SLP nutrient delivery technology on properties of live human blood. (2015) (3)
GENETIC PREDISPOSITION TO ALCOHOLISM: ASSOCIATION OF THE B1 ALLELE OF THE DRD2 RECEPTOR GENE IN SEVERE ALCOHOLICS. (1992) (2)
A Treatise on the Role of Herpesvirus in Neurodegeneration (2020) (2)
Calvin klein (CK) designer cocktail, new “Speedball” is the “grimm reaper”: Brain dopaminergic surge a potential death sentence (2020) (2)
Translational and Molecular Cytoarchitectural Genetic Guided Therapy to Induce Dopamine Homeostatic Neuro-signaling in Reward Deficiency and Associated Drug and Behavioral Addiction Seeking: A 60 Year Sojourn the Future is Now. (2021) (2)
Correction: Braverman, E.R., et al. Managing Terrorism or Accidental Nuclear Errors, Preparing for Iodine-131 Emergencies: A Comprehensive Review. Int. J. Environ. Res. Public Health 2014, 11, 4158–4200 (2014) (2)
Reward Deficiency Syndrome (RDS): Entering the Genomics and Neuroscience Era of Addiction Medicine (2015) (2)
Neuropsychiatric Genetics of Happiness, Friendships and Politics: A New Era in Understanding Social Interface (2012) (2)
Hypothesizing that Putative Dopaminergic, Melatonin, Benzodiazepine Reward Circuitry Receptor(s) Activator Provides Sleep Induction Benefits (2014) (2)
Generational association studies of Dopaminergic genes in Reward Deficiency Syndrome (RDS) subjects (2013) (2)
Genome Wide Sequencing Compared to Candidate Gene Association Studies for Predisposition to Substance Abuse a Subset of Reward Deficiency Syndrome (RDS): Are we throwing the Baby Out with the Bathwater? (2014) (2)
Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation (2022) (2)
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse? (2019) (2)
Raising Endogenous Brain Levels of Kynurenic Acid May Produce Anti-Reward and Enhance Suicide Ideation (2014) (2)
Neuroquantum Theories of Psychiatric Genetics: Can Physical Forces Induce Epigenetic Influence on Future Genomes? (2015) (2)
Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence? (2022) (2)
Epigenetics in Neuropsychiatry (2011) (2)
Buprenorphine and Naloxone Combinations and Dopamine (2018) (2)
The long-term interaction of diet and dopamine D2 gene expression on brain microglial activation (2021) (2)
Coupling the Genetic Addiction Risk Score (GARS),? Comprehensive Analysis of Reported Drugs (CARD)? and KB220Z? showing reward circuitry activation of dopaminergic pathways in Reward Deficiency Syndrome (RDS): A paradigm shift (2013) (2)
Hypothesizing Benefits of the Incorporation of Genetic Addiction Risk Score (GARSRX™Rx™) and Dopamine Agonist Modalities (DAM) in Clinical Addiction Medicine. (2014) (2)
Dopaminylation in Psychostimulant Use Disorder Protects Against Psychostimulant Seeking Behavior by Normalizing Nucleus Accumbens (NAc) Dopamine Expression. (2021) (2)
The Marc Pro TM Device is a Novel Paradigm Shift in Muscle Conditioning, Recovery and Performance: Induction of Nitric Oxide (NO) Dependent Enhanced Microcirculation Coupled with Angiogenesis Mechanisms (2011) (2)
A short term pilot open label study to evaluate efficacy and safety of LG 839 , a customized DNA directed nutraceutical in obesity : Exploring Nutrigenomics Research (2009) (2)
Coupling Neurogenetics ( GARS TM ) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome ( RDS ) : Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms Journal of Reward Deficiency Syndrome (2016) (2)
Possible Rationale for Differential Chemotherapy of Depression In Humans: A Review of the Biogenic Amine Hypothesis Part I (1976) (1)
Invited Commentary: In a Genomic Era, Should We Promote Dopamine Homeostasis to Treat Opiate/ Opioid Abuse, Instead of Blocking Brain Dopamine Function? (2017) (1)
Translational Research to Uncover Diagnostic & Therapeutic Gene Targets Emerging in a Genomic Era: from Bench to Bedside (2012) (1)
Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise (2021) (1)
Neurogenetics and nutrigenomics of reward deficiency syndrome (RDS): Stratification of addiction risk and mesolimbic nutrigenomic manipulation of hypodopaminergic function (2013) (1)
Correction: Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics (2015) (1)
Neurochemical and Clinical Aspects of Acupuncture & Auriculotherapy: Adaptation in United States for Substance Use Disorder (SUD), a Clinical Subtype of Reward Deficiency Syndrome (RDS) (2007) (1)
Opioid and dopamine genes interact to predict precision naltrexone response in alcohol use disorder: Interpretation misfires (2021) (1)
Reward Deficiency Solution System (RDS): A Tale of Three Scientists (2014) (1)
The Reward Deficiency Syndrome and Links with Addictive and Related Behaviors (2021) (1)
Understanding that Addiction Is a Brain Disorder Offers Help and Hope (2022) (1)
Iatrogenic opioid dependence is endemic and legal: Genetic addiction risk score (GARS) with electrotherapy a paradigm shift in pain treatment programs (2013) (1)
Endorphinergic Enhancement Attenuation of Post-traumatic Stress Disorder (PTSD) via Activation of Neuro-immunological Function in the Face of a Viral Pandemic. (2021) (1)
“Cold” X5 Hairlaser™ used to treat male androgenic alopecia and hair growth: an uncontrolled pilot study (2014) (1)
Combined chronic oral methylphenidate and fluoxetine treatment during adolescence: Effects on behavior. (2022) (1)
Why haven't we solved the addiction crisis? (2022) (1)
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids (2022) (1)
Embracing Reward Deficiency Syndrome (RDS) Solution System: A Genomic Thrust (2015) (1)
Rapid Anti-Depressant Relief by Ketamine: Exploring A Complex Mechanism of Action (2019) (1)
Preliminary Hormonal Correlations in Female Patients as a Function of Somatic and Neurological Symptom Clusters: An Exploratory Development of a Multi-Hormonal Map for Bio-Identical Replacement Therapy (MHRT) (2013) (1)
Hypothesizing “Reward” Gene Polymorphisms May Predict High Rates of Injury and Addiction in the Workforce: A Nutrient and Electrotherapeutic Based Solution (2014) (1)
Utilization Of Bayes' Theorem To Estimate The Predictive Value Of The A1 Allele Of The D2 Dopamine Receptor Gene In Compulsive Disease (1994) (1)
Bariatric surgery: Potential post-operative heightened sensitivity to substances or behaviors (2021) (1)
Hypothesizing Major Depression as a Subset of Reward Deficiency Syndrome (RDS) Linked to Polymorphic Reward Genes: Considerations for Translational Medicine Approaches for Future Drug Development (2019) (1)
Editors & Editorial board (2018) (1)
Reward Dependence and Reward Deficiency (2016) (1)
Proposing FDA consideration for the treatment and prophylaxis of opioid and psychostimulant abuse to incorporate the induction of DNA guided dopamine homeostasis: Anti-reward deficiency restoration solution (ARDS) (2020) (1)
Prenatal Effects of Nicotine on Obesity Risks: A Narrative Review (2022) (1)
Hypothesizing Molecular Genetics of the Holocaust: Were Dopaminergic Genes Involved or Brain Wash? (2016) (1)
Meet Our Regional Editor (2019) (0)
Reward Deficiency Syndrome Solution System (RDSSS) A Genetically Driven Putative Inducer of "Dopamine Homeostasis" as a Futuristic Alternative to Enhance Rehabilitation Instead of Incarceration. (2023) (0)
Meet Our Editor-in-Chief (2021) (0)
Using “ Genetic Precision Medicine ” to Treat and Prevent Obesity : Induction of “ Dopamine Homeostasis ” (2017) (0)
Alcoholism: scientific basis and chemotherapeutic control. (1986) (0)
Allelic compound of the human dopamine (D2) receptor gene in alcoholism as kompulsionsstörungen (1991) (0)
Report on 2nd International Conference on Addiction Medicine and Reward Deficiency Syndrome (ARDS 2017) (2017) (0)
Precision Behavioral Management (PBM) A Novel Approach to Combat Post-Traumatic Stress Disorder (PTSD). (2018) (0)
Author ' s response to reviews Title : Age-related increases in parathyroid hormone may be antecedent to both osteoporosis and dementia : a clinical study (2008) (0)
Genetic Addiction Risk Testing Coupled with Pro-Dopamine Homeostasis, and Electro Therapy, May Overcome Aberrant Reward Seeking Behaviors: Analytic Evidence (2018) (0)
The DRD2 Taq1A A1 Allele May Magnify the Risk of Alzheimer’s in Aging African-Americans (2017) (0)
21. – METABOLIC STEREOSPECIFICITY OF OPIATE AGONIST AND ANTAGONIST DRUGS (1977) (0)
ORDER granting 62 Motion for Attorney Fees For the reasons set forth herein, the Court awards plaintiffs $145,246.44 in attorneys' fees and $3,385.85 in costs. SO ORDERED. Ordered by Judge Joseph F. Bianco on 10/24/2016. (Shea, Zoe) (2016) (0)
Coupling Genetic Addiction Risk Score (GARS) and (2017) (0)
Book Reviews (1999) (0)
Fatty Acid-Binding Protein 5 Gene Deletion Enhances Nicotine-Conditioned Place Preference: Illuminating the Putative Gateway Mechanisms (2023) (0)
Health economics of nutrigenomics in weight management Research (2008) (0)
Reward Deficiency Syndrome (RDS): Is there a Solution? (2014) (0)
Kenneth Blum 1,5,6,8,10,11,12,15*, Marlene Oscar-Berman2, Elizabeth Stuller3, David Miller4,5, John Giordano6, Siobhan Morse6, Lee McCormick7, William Downs B5, Roger L Waite5, Debmalya Barh8, Dennis Neal9, Eric R Braverman1,10, Raquel Lohmann10, Joan Borsten11, Mary Hauser12, David Han13, Yijun Liu (2012) (0)
Over-the-counter (OTC) drugs (1984) (0)
Genetic addiction risk score analysis: hypodopaminergic polymorphic risk alleles in polydrug addicted males and meso-limbic dopaminergic agonistic activation by neuroadaptagen amino-acid therapy (2011) (0)
Neuropsychopharmacology and Neurogenetic Aspects of Executive Functioning: Should Reward Gene Polymorphisms Constitute a Diagnostic Tool to Identify Individuals at Risk for Impaired Judgment? (2012) (0)
Report on the Inaugural Reward Deficiency Syndrome Summit (RDS-1) (2015) (0)
Treating Reward Deficiency Syndrome (RDS) with a nutrigenomic dopaminergic brain activator by targeting reward gene polymorphisms utilizing genetic algorithms (2018) (0)
Dopaminergic and other genes related to reward induced overeating, Bulimia, Anorexia Nervosa, and Binge eating (2021) (0)
Reply (1994) (0)
Genetic Addiction Risk and Psychological Profiling Analyses for “Preaddiction” Severity Index (2022) (0)
Exercise Modulates Brain Glucose Utilization Response to Acute Cocaine (2022) (0)
A Systems Biological Approach Coupling Reward Gene Polymorphisms and aNutraceutical (KB220Z) Pro-Dopamine Regulator (PDR) as Putative“Standard of Care” to Treat Reward Deficiency Syndrome (RDS): EmergingEvidence - Based Scientific Induction of “Dopamine Homeostasis” (2020) (0)
Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) Testing (2022) (0)
Significantly Attenuates Aberrant Mood in Residential Patient Addiction Treatment : Putative Activation of Dopaminergic Pathways in the MesoLimbic Reward Circuitry of Humans (2011) (0)
P-109 Subclinical hyperparathyroidism, an age dependent phenomena, is an antecedent of both osteoporosis and dementia (2007) (0)
Reward Deficiency Solution System (RDSS) "Repairing a Hypodopaminergic Trait/State: Reflection Over 50 Years (2014) (0)
Offering a Putative “Dopamine Homeostatic” Solution to Overcome the Perils of Reward Deficiency Syndrome (RDS) Epidemic: Emergence of “Precision Behavioral Management (PBM)” (2020) (0)
Drugs: Have It Your Way or The Burger King Syndrome (1977) (0)
Pro-Dopamine Regulator-( KB 220 ) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome ( RDS ) Mini-review (2017) (0)
DIFFERENTIAL BRAIN RECEPTOR STIMULATION BY NOREPINEPHRINE AND SEROTONIN: POSSIBLE RATIONALE FOR DIFFERENTIAL CHEMOTHERAPY OF DEPRESSION IN HUMANS (1979) (0)
Customized DNA–directed precision nutrition to balance the brain reward circuitry and reduce addictive behaviors (2018) (0)
Genetic Addiction Risk Score (GARS): Molecular Neurogenetic Evidence for Predisposition to Reward Deficiency Syndrome (RDS) (2014) (0)
Fall 2012 Abstract Titles: 11th Annual ASRA Pain Medicine Meeting, November 15–18, 2012, Miami, Florida (2013) (0)
Mesolimbic Reward Circuitry and Reward Deficiency Syndrome (RDS): A Commentary on Long Term Dopaminergic Therapy (2008) (0)
Understanding the Importance of Dopaminergic Deficit in Reward Deficiency Syndrome (RDS): Redeeming Joy Overcoming "Darkness" in Recovery (2015) (0)
DRAFT DOCUMENT NeuroGenesis , inc . New Insights Into the Causes of Alcoholism (0)
How to Combat the Global Opioid Crisis (2023) (0)
Reward Deficiency Syndrome Model of Addiction Psychiatry: Everywhere, Everything, and All at Once (2022) (0)
The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS). (2023) (0)
Nutrigenomics of Neuradaptogen Amino-Acid-Therapy and Neurometabolic Optimizers: Overcoming carbohydrate bingeing and overeating through neurometabolic mechanisms (2011) (0)
A pharmaceutical composition for the treatment of cocaine addiction. (1988) (0)
Positive Clinical Outcomes for Severe Reported Pain Using Robust Non-Addictive Home Electrotherapy—A Case-Series (2023) (0)
Genetic addiction risk score (GARSrx), comprehensive analysis of reported drugs (CARD) dopamine agonist therapy (kb220z): Embracing genetic prediction of addiction risk severity for pain and addiction treatment (2014) (0)
The Control of the Cardiovascular and Central Nervous System. (1974) (0)
Hypothesising that salts of iodine, strontium and caesium reverse ageing induced by nuclear radiation (2013) (0)
Can We Combat Reward Deficiency Behaviors (RDS) including Substance Use Disorder (SUD) through Genetic Risk Screening coupled with Precision Pro-Dopamine Regulation by Algorithmic matched Polymorphic Allelic Risks (2019) (0)
Editors' Foreword (1993) (0)
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner? (2015) (0)
Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization (2019) (0)
A 21ST CENTURY PERSPECTIVE ON DEPRESSION, REWARD GENES, AND DNA POLYMORPHIC TARGETED NUTRIGENOMIC RESOLUTION (2017) (0)
Neuroimaging in Psychiatry and Neurology: Current Status and Future Directions (2016) (0)
Meet Our Editorial Board Member (2019) (0)
PRBM_A_292958 2115..2134 (2021) (0)
Substance abuse vulnerability and 02 receptor genes disease (1993) (0)
Hypothesizing Music Intervention Enhances Brain Functional Connectivity Involving Dopaminergic Recruitment: Common Neuro-correlates to Abusable Drugs (2016) (0)
An Iron-Free VMP35 Multi-nutrient Complex Modulates an Array of Homeostatic Biological Parameters: Promoting Hemoglobinization, Aerobic Metabolism, Viral Immuno-competence, and Inflammatory Regulation (2020) (0)
Genetic Addiction Risk Score (GARS®) as a Predictor of Reward Deficiency Syndrome (RDS): Identifying Predisposition Not Diagnosis (2019) (0)
The genetics of pathological gambling disorder: a systematic review [forthcoming] (2013) (0)
Future Perspective: Paving a Path to Optimization of Health (2011) (0)
Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequalae in Substance Use Disorder (SUD) in Fifty Cases. (2022) (0)
Transmodulation of Dopaminergic Signaling to Mitigate Hypodopminergia and Pharmaceutical Opioid-induced Hyperalgesia (2020) (0)
“Preaddiction” construct and reward deficiency syndrome: genetic link via dopaminergic dysregulation (2022) (0)
Disorders & Genetic Reports (2012) (0)
Cannabis, a Bio-Spiritual Remedy for Addiction (2019) (0)
Behavioral, Neurochemical and Developmental Effects of Chronic Oral Methylphenidate: A Review (2023) (0)
Reward Deficiency Solution System(RDSS): Changing the landscape of treatment and relapse prevention for all addictions utilizing evidence- based research in humans and animal models (2013) (0)
Molecular Neurobiology of Recovery with the Twelve Steps (2013) (0)
Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of “Dopamine Homeostasis” (2022) (0)
Polygenic and multi locus heritability of alcoholism: Novel therapeutic targets to overcome psychological deficits (2020) (0)
Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia’s Effect on Addictive and Non-Addictive Behaviors in a Nuclear Family (2022) (0)
Offering a putative neurobiological “dopamine homeostatic” solution to overcome the perils of the reward deficiency syndrome pandemic: emergence of “precision behavioral management” (2022) (0)
Evolutionary impact on dopaminergic genes and societal issues related to ethnicity, sex, drugs, music, politics, friendships, marriage, longevity and happiness: Ancestral polymorphisms and society (2013) (0)
Effects of Combined Stresses of AF Operations and Medication on Cardiovascular and Nervous Functions. (1978) (0)

This paper list is powered by the following services:

Other Resources About Kenneth Blum

en.wikipedia.org

What Schools Are Affiliated With Kenneth Blum?

Kenneth Blum is affiliated with the following schools: